logo
episode-header-image
Aug 15
22m 43s

The Impact of Nonhealth Policies in a Ti...

JAMA NETWORK
About this episode

The second Trump administration launched several actions in 2025 that directly affect the health of populations. Sara Bleich, PhD, of Harvard Chan School of Public Health joins JAMA Health Forum Editor in Chief Sandro Galea, MD, DrPH, to discuss the nonhealth policies that may matter most to health and warrant ever-more attention, particularly in a moment of policy turbulence.

Related Content:

Up next
Jul 11
The Evolution of Artificial Intelligence and Regulation
The evolution of artificial intelligence technology has outstripped most health policy oversight in the US. Michelle M. Mello, JD, PhD, Professor of Law and Professor of Health Policy at Stanford University, discusses this and more with JAMA Health Forum Editor in Chief Sandro Ga ... Show More
26m 27s
Jun 13
Improving Health and Health Care Affordability in the US with David Cutler
The US is an outlier in health system performance, spending more than other peer countries while performing worse. US economist David Cutler, who is the Otto Eckstein Professor of Applied Economics at Harvard University, discusses this and more with JAMA Health Forum Editor in Ch ... Show More
22m 15s
May 16
The Threat to Health Insurance Coverage in the US
Increased health insurance coverage in the US has had a broad range of positive impacts on US health, including increases in preventive care and better chronic disease management. Larry Levitt, MPP, of KFF joins JAMA Health Forum Editor in Chief Sandro Galea, MD, DrPH, to discuss ... Show More
14m 33s
Recommended Episodes
Jul 29
Managing Adverse Effects of Obesity Medications
New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights ar ... Show More
12m 21s
Jul 2024
Obesity Medications
New weight-loss drugs have transformed care for people with obesity. In this Clinical Reviews podcast, Robert F. Kushner, MD, MS, of Northwestern University Feinberg School of Medicine joins JAMA Deputy Editor Mary McGrae McDermott, MD, to discuss prescribing these drugs to impro ... Show More
17m 54s
Sep 2019
National Obesity Care Week with Dr. Chandra
Join Dr. Chandra as she discusses the importance of understanding the risks of obesity and how we can address the disease during National Obesity Care Week. 
3m 34s
Aug 2024
Obesity in Adolescents
About 20% of adolescents in the US are living with obesity. Author Aaron S. Kelly, PhD, of the University of Minnesota Medical School joins JAMA Senior Editor Karen E. Lasser, MD, MPH, to discuss Obesity in Adolescents: A Review. Related Content: Obesity in Adolescents 
18m 56s
Feb 2025
America’s Obesity Crisis: Is Ozempic a Cure or a Cover-Up? | Calley Means and Tyna Moore
The rise in obesity and chronic disease over the years is alarming. Rather than genetics, it can be attributed to environmental and dietary changes, emphasizing the role of food quality over quantity. And while GLP-1 agonists like Ozempic may show some promise in addressing metab ... Show More
1h 4m
Jul 23
122 | How to Support Patients on Obesity Medications: A Short Course on Side Effects, Satiety & Supplements
Join The Obesity Medicine Nutrition Course! Enter code POD15 at checkout for 15% off!Anti-obesity medications are everywhere—but they also come with new challenges. From rapid weight loss and side effects to TikTok-fueled supplement questions, patients on weight management medica ... Show More
29m 21s
Oct 2024
#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter dives back into the increasingly popular topic of GLP-1 agonists, such as Ozempic and Mounjaro, which ... Show More
20m 36s
Oct 2024
#537: Appetite Regulation, Metabolic Compensation and More – Stephan Guyenet, PhD
This is an “ask me anything” (AMA) episode with Dr. Stephan Guyenet, an expert in obesity neuroscience and eating behavior. This episode was originally published on Sigma Nutrition Premium. If you’re interested in subscribing to Sigma Nutrition Premium, then check all the details ... Show More
1h 4m
Jul 2024
Tara Swart (Neuroscientist): The Science Behind Stress, Body Fat & Manifestation (E273)
In this episode, respected neuroscientist and author Dr. Tara Swart joins Jake to uncover fascinating perspectives about the complex interplay between our brains and bodies. Tara sheds light on how our constant smartphone use impacts us both mentally and physically, and what we c ... Show More
56m 42s
Dec 2024
How Ozempic Transformed the Way We Look at Obesity
Ozempic, Wegovy, and Mounjaro, are being called “miracle drugs” with users boasting about their fast results. Dr. Sanjay Gupta takes a deep dive into how they disrupted the entire weight loss industry and changed the conversation about obesity.  Learn more about your ad choices. ... Show More
25m 47s
Listen to millions of songs and podcasts on Anghami